Brain cancer immunology: CCL3's role in boosting immune attack on tumors
Official title: Clinical Neuroimmunology of CCL3 in Brain Tumors
Funded at Duke University · NIH-11321164 · Data updated 2026-11-12
A Duke University team is studying how the CCL3 chemical signal helps the immune system fight glioblastoma by improving dendritic cell work and T cell movement.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project start | May 1, 2024 |
| Project end | April 30, 2029 |
| Funding year | 2026 |
| Award (this year) | $313,504 |
| NIH project number | 5R01CA289789-03 |
| Project ID | NIH-11321164 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with malignant brain tumors, particularly glioblastoma, who may benefit from enhanced immune-based therapies in future clinical settings.
✕Less likely to help
Patients whose tumors do not rely on CCL3 pathways or who cannot tolerate immune-based approaches may not benefit.
What this research studies
This project looks at why glioblastoma, a deadly brain tumor, evades the immune system and how a molecule called CCL3 might improve immune responses. Researchers will examine how CCL3 affects dendritic cell migration to lymph nodes and the activation of tumor-specific T cells, with the goal of timing and enhancing immune attack on cancer cells. The work focuses on translating these findings toward strategies that could boost patient responses to immunotherapies while reducing immune suppression seen in brain tumor patients. The study leverages preclinical data and clinical observations to inform potential future trials in humans.
Why it matters
Potential benefit: If successful, this work could lead to more effective immunotherapies for brain tumor patients by improving immune cell trafficking and activation against cancer cells.
How similar studies have gone: Previous approaches using dendritic cell vaccines show occasional strong responses, but overall results are modest, making this a promising but exploratory next step.
Where this research is happening
-
Duke University
Durham, United States Active
Researchers
- Principal investigator: Gunn, Michael D — Duke University
- Study coordinator: Gunn, Michael D
Related research
Other NIH-funded projects on the same topics.
-
ONC206 for children with brain tumors: a first-in-children trial
A first-in-children trial will test the safety and early signs of effectiveness of ONC206, taken by mouth, in kids with malignant brain tumors like diffuse midline gliomas.
-
ONC206 for children with malignant brain tumors
A first-in-children trial tests the safety and early effectiveness of a pill that can cross the brain barrier to treat pediatric brain tumors.
-
ONC206 for children with dangerous brain tumors
A first-in-children study tests the safety and early effectiveness of an oral drug, ONC206, for kids with high-risk brain tumors that have spread or recurred.
-
Oral bacteria and brain metastasis: how the mouth may influence brain tumors
A study exploring how oral microbes may affect brain metastases and patient outcomes, with potential to guide new microbiome-based approaches.
-
Bioengineered brain barrier chip to improve drug screening for brain tumors
A small, patient-friendly brain barrier chip is being developed to test drugs for glioblastoma more accurately before they reach clinical trials.
-
Understanding how epigenetic changes drive pediatric brain tumor recurrence and how reversing them could help
A pediatric brain cancer research project is exploring how an epigenetic change (H3K27M) and tumor environment contribute to tumor coming back, using a reversible mouse model to study potential ways to prevent recurrence.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.